June 25, 2021 10:08 AM EDTUpdated July 14, 07:58 AM
Peer Review

With Glax­o­SmithK­line in the rearview mir­ror, Ab­bas Hus­sain is ready to lead a biotech of his own; Doug Tre­co scores first CEO job since Ra Phar­ma buy­out

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Ab­bas Hus­sain was once con­sid­ered to be a top can­di­date to take An­drew Wit­ty’s place as CEO of Glax­o­SmithK­line in 2016. When the job …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Why Re­gen­eron is buy­ing 23andMe

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times